Trial Profile
Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI at least 2) Diffuse Large B-Cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Methotrexate; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHIC
- 02 Mar 2020 Status changed from active, no longer recruiting to completed.
- 06 Nov 2019 Results (n=96) of two clinical studies: a phase 2 trial; dose-dense chemoimmunotherapy (NCT01502982) and a early systemic CNS prophylaxis with high-dose methotrexate (CHIC or NCT01325194), assessing clinical feasibility and prognostic value of ctDNA in prospectively collected samples from high risk B-cell lymphoma patients, released in 61st Annual Meeting and Exposition of the American Society of Hematology
- 04 Sep 2017 Status changed from recruiting to active, no longer recruiting.